Condition: Cancer · Pediatric Cancer · Lymphoblastic Lymphoma (LBL) · Sponsor: Resonance, Inc.
Cancer is a leading cause of illness and death among children, adolescents, and young adults(CAYAs), especially in low- and middle-income countries(LMICs), where access to timely diagnosis and treatment is often limited. As a result, patients in these settings may experience higher rates of treatment complications, interruptions, and poorer outcomes compared with those in high-income countries (HICs). This is a prospective, multicenter observational study that will follow children, adolescents, and young adults(CAYAs) with cancer who are receiving routine care at participating hospitals in low - and middle - income countries(LMICs). The study does not involve experimental treatments or changes to standard medical care. Information will be collected from medical records and from questionnaires that address access to care and social factors affecting treatment. By describing treatment outcomes and the challenges patients and families face during cancer care, this study aims to provide data that can help inform future efforts to improve access to care and cancer outcomes in resource-limited settings.
This description comes directly from the study's public registry record.
Gabriela Villanueva, MD. · +1-901-205-9518 · gabriela.villanueva@resonancehealth.org
Always discuss trial participation with your own doctor first.
| Yeolyan Center for Cancer and Blood Disorders | Yerevan, Armenia | Recruiting |
| The Children's Cancer Hospital Egypt 57357 | Cairo, Egypt | Recruiting |
| Unidad Nacional de Oncología Pediátrica (UNOP) | Guatemala City, Guatemala | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07632014